Dr. Lawrence Leichman, AGICC Medical Director, will lead an Investigators’ Meeting – June 2, 2012 (11:30am – 1:30 pm) that includes some of the country’s premier GI cancer experts. The meeting agenda will feature updates and protocol discussions on current studies, as well as presentations by companies collaborating with AGICC on clinical trials.Continue reading
Larry Leichman, MD (AGICC Medical Director) and Steve Cohen, MD (PI at Fox Chase Cancer Center) were notified on April 9th that the OSI abstract submitted to ASCO 2012 was accepted as a poster and is scheduled for presentation Monday, June 4th, 8AM-12 noon.Continue reading
CORE Science Solutions (CSS) Consortia, the Academic Gastrointestinal Cancer Consortium (AGICC) and Academic Myeloma Consortium (AMyC) will have a presence at the 2012 ASCO meeting June 1-4 in Chicago, IL.Continue reading
The Aptium Oncology GI Cancer Consortium (AGICC) will have a presence at the 2011 Gastrointestinal Cancers Symposium, 20-22, 2011 at The Moscone West Building in San Francisco. The symposium, also known as the GI ASCO, will feature more than 600 abstracts on the latest research in gastrointestinal cancers.Continue reading
Criterium, Inc., a full-service, global CRO, is pleased to announce the acquisition of the former Aptium Oncology’s CORE Science Solutions (CSS) Cancer Consortium Groups consisting of AGICC and AMyC as the newest members of Criterium’s Pharma services companies. Criterium is proud to include AGICC and AMyC, two academic cancer research consortia in its family of companies. Important and well-known institutions and investigators are actively collaborating as part of the consortia.Continue reading
Dr. Lawrence Leichman, Director of the Aptium Oncology GI Cancer Consortium (AGICC), presented two posters at the ASCO-NCI-EORTC Annual Meeting held in Hollywood, Florida October 17-18, 2010.
The posters are the first publications from the AGICC trials. The first poster, titled ‘DNA Repair and Apoptosis,’ was authored by Dr. Leichman and members of the Consortium. The second poster pertains to a Phase II study of a combination compound for advanced colorectal cancer.Continue reading
Aptium Oncology’s Research Department featured two consortia at the recent ASCO 2010 Annual Meeting in Chicago which was aptly themed ‘Advancing Quality through Innovation.’ More than 30,000 cancer specialists from around the world gather at this premier meeting annually to discuss the latest innovations in research, quality, practice and technology in cancer.Continue reading
Lawrence P. Leichman, MD, FACP, Director of the Aptium Oncology GI Cancer Consortium (AGICC) and an oncologist at the Comprehensive Cancer at Desert Regional Hospital in Palm Springs, CA, recently wrote an editorial titled ‘On Target? Off Target? Why We Really Do Not Know’ for the Journal of Clinical Oncology, ASCO’s official publication.Continue reading
Join us for our Myeloma and GI Cancer Consortia Reception
Friday, June 4, 2010 6:30 – 8:30 pm
Affinia Chicago • C-View – Rooftop Lounge
166 East Superior Street
Chicago, IL 60611
Please RSVP by Friday, May 21 to Rhonda Hopkins at firstname.lastname@example.org.
Bus Route from the Convention Center: Gate 3 Route 6
Network with our investigators. Visit our booth #22036.
An editorial by Dr. John S. Macdonald, Aptium Oncology’s Chief Medical Officer, was recently published in the GI Cancer Research Journal, the official journal of the International Society of Gastrointestinal Oncology. The editorial is titled Adopting Postoperative Chemoradiotherapy in Resected Gastric Cancer.Continue reading